<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002844</url>
  </required_header>
  <id_info>
    <org_study_id>DM90-106</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-90106</secondary_id>
    <secondary_id>NCI-G96-1034</secondary_id>
    <secondary_id>CDR0000065081</secondary_id>
    <nct_id>NCT00002844</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Bone Marrow Transplantation for Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with bone marrow transplantation may
      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating
      patients with chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Examine the potential role for high dose cyclophosphamide, total body irradiation
      and bone marrow transplantation for patients with chronic lymphocytic leukemia who are at
      high risk for disease progression.

      OUTLINE: Patients receive daily intravenous infusions of cyclophosphamide for two days,
      followed by total body irradiation in four daily exposures. After completion of the total
      body irradiation, allogeneic or autologous bone marrow is infused intravenously.

      PROJECTED ACCRUAL: 50 patients are expected to be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1991</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of high dose cyclophosphamide, total body irradiation and bone marrow transplantation for chronic lymphocytic leukemia</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide + TBI + BMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Daily intravenous infusions of cyclophosphamide for two days,</description>
    <arm_group_label>Cyclophosphamide + TBI + BMT</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.</description>
    <arm_group_label>Cyclophosphamide + TBI + BMT</arm_group_label>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Bone Marrow Transplantation</intervention_name>
    <description>After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.</description>
    <arm_group_label>Cyclophosphamide + TBI + BMT</arm_group_label>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.</description>
    <arm_group_label>Cyclophosphamide + TBI + BMT</arm_group_label>
    <other_name>radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Chronic lymphocytic leukemia (CLL) patients after initial relapse
        who have achieved a complete or partial remission with fludarabine therapy or after initial
        relapse or progression Prolymphocytic leukemia in first remission or after relapse Patients
        15-65 years old who lack an HLA-identical sibling are eligible for autologous BM
        transplantation Patients 16-50 years old with an HLA identical or one antigen mismatched
        related donor are eligible for allogeneic BM transplantation

        PATIENT CHARACTERISTICS: Age: 15-65 (See Disease Characteristics) Performance status:
        Zubrod no more than 2 Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5
        mg/dL Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: Cardiac ejection fraction
        at least 50% Pulmonary: DLCO at least 50% of predicted Other: No severe concomitant medical
        or psychiatric illnesses

        PRIOR CONCURRENT THERAPY: No extensive prior radiotherapy which would prevent
        administration of total body radiation Patients may also participate in study MDA-DM-92082
        for retroviral gene marking of the autologous marrow and blood cells
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>total body irradiation</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>allogeneic</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

